GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Operating Margin %

Biotech Acquisition Co (Biotech Acquisition Co) Operating Margin % : 0.00% (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Biotech Acquisition Co's Operating Income for the three months ended in Sep. 2022 was $-0.25 Mil. Biotech Acquisition Co's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Therefore, Biotech Acquisition Co's Operating Margin % for the quarter that ended in Sep. 2022 was 0.00%.

The historical rank and industry rank for Biotech Acquisition Co's Operating Margin % or its related term are showing as below:


BIOT's Operating Margin % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 3.8
* Ranked among companies with meaningful Operating Margin % only.

Biotech Acquisition Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Biotech Acquisition Co's Operating Income for the three months ended in Sep. 2022 was $-0.25 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.74 Mil.


Biotech Acquisition Co Operating Margin % Historical Data

The historical data trend for Biotech Acquisition Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Operating Margin % Chart

Biotech Acquisition Co Annual Data
Trend Dec20 Dec21
Operating Margin %
- -

Biotech Acquisition Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Operating Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Biotech Acquisition Co's Operating Margin %

For the Shell Companies subindustry, Biotech Acquisition Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotech Acquisition Co's Operating Margin % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Biotech Acquisition Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Biotech Acquisition Co's Operating Margin % falls into.



Biotech Acquisition Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Biotech Acquisition Co's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-1.57 / 0
= %

Biotech Acquisition Co's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=-0.247 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotech Acquisition Co  (NAS:BIOT) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Biotech Acquisition Co Operating Margin % Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Traded in Other Exchanges
N/A
Address
545 West 25th Street, 20th Floor, New York, NY, USA, 10001
Website
Biotech Acquisition Co is a blank check company.
Executives
Albert F Hummel director, officer: Chief Investment Officer PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc 10 percent owner 545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari director 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry officer: Chief Operating Officer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer director, 10 percent owner, officer: Chief Executive Officer 545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci officer: CFO & Treasurer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001

Biotech Acquisition Co (Biotech Acquisition Co) Headlines

From GuruFocus

Biotech Acquisition Company Announces Liquidation

By Stock market mentor Stock market mentor 02-02-2023

Biotech Acquisition Company Announces Liquidation

By GlobeNewswire GlobeNewswire 02-02-2023